The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1126
March 18, 2002
View Complete Issue         Table of Contents 2019 
Desloratadine (Clarinex)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Desloratadine (Clarinex)
March 18, 2002 (Issue: 1126)
Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine (Claritin), has been approved by the FDA for oral treatment of allergic rhinitis and chronic urticaria in patients at least 12...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Desloratadine (Clarinex)
Article code: 1126b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.